$CRVS

Corvus Pharmaceuticals Inc

$CRVS

Corvus Pharmaceuticals Inc

Past 12mo:4mentions4voices

All voices2 calls since Jan 2026show all

Loading price chart…

Recent calls

2 calls

@acinvestorblogJan 20, 2026 · 9:01 PM

$CRVS offering Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Corvus. In addition, Corvus expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $22,500,000 of shares of common stock at the public offering price less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Open on X

@adamfeuersteinJan 20, 2026 · 12:04 PM

$CRVS Corvus pill shows promise in early-stage eczema trial 75% of participants treated with soquelitinib achieved EASI 75 after 8 weeks compared to 20% of placebo participants offered a placebo. https://t.co/XlOmX0GUZf

Open on X

About this stock

$CRVS has garnered attention from four distinct FinTwit voices over the past two months, with four total mentions between November 27, 2025 and January 20, 2026. The biotech sector dominates discussion of Corvus Pharmaceuticals, with voices including @adamfeuerstein, @acinvestorblog, @jacobplieth, and @photonbull each contributing one mention. The most recent activity centered on two separate announcements: a clinical trial update showing early-stage efficacy data and a $150 million equity offering.

AI-generated from tracked posts · updated Jul 11, 2026